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ABSTRACT  
Optical coherence tomography (OCT) has gained wide adoption in biological and medical imaging due to its exceptional tissue 
penetration, 3D imaging speed and rich contrast. However, OCT plays a relatively small role in molecular and cellular imaging 
due to the lack of suitable biomolecular contrast agents. In particular, while the green fluorescent protein has provided 
revolutionary capabilities to fluorescence microscopy by connecting it to cellular functions such as gene expression, no equivalent 
reporter gene is currently available for OCT. Here we introduce gas vesicles, a unique class of naturally evolved gas-filled protein 
nanostructures, as the first genetically encodable OCT contrast agents. The differential refractive index of their gas compartments 
relative to surrounding aqueous tissue and their nanoscale motion enables gas vesicles to be detected by static and dynamic OCT 
at picomolar concentrations. Furthermore, the OCT contrast of gas vesicles can be selectively erased in situ with ultrasound, 
allowing unambiguous assignment of their location. In addition, gas vesicle clustering modulates their temporal signal, enabling 
the design of dynamic biosensors. We demonstrate the use of gas vesicles as reporter genes in bacterial colonies and as purified 
contrast agents in vivo in the mouse retina. Our results expand the utility of OCT as a unique photonic modality to image a wider 
variety of cellular and molecular processes.
INTRODUCTION  
Optical coherence tomography (OCT) occupies a unique 
niche as an optical imaging modality that can visualize 
biological structures and processes with the spatial resolution 
of microns, the temporal resolution of milliseconds and a 
penetration depth of 1-3 mm1, 2. Since its invention, OCT has 
found utility in a wide range of scientific and clinical 
applications, ranging from the study of bacterial biofilms to 
medical specialties such as ophthalmology, gastroenterology, 
cardiology, dermatology and pulmonology3-9. Despite this 
widespread use, OCT currently has a limited role in cellular 
and molecular imaging due to the lack of imaging agents 
capable of connecting OCT contrast to biological processes 
such as gene expression. In particular, while fluorescence 
microscopy takes advantage of synthetic fluorophores and 
genetically encoded reporters such as the green fluorescent 
protein (GFP) to visualize a wide variety of cellular functions, 
few widely used synthetic contrast agents and no reporter genes 
are currently available for OCT.  
OCT typically relies on the backscattering of near-
infrared (NIR) light by endogenous scatterers such as cell 
nuclei and mitochondria to resolve tissue morphology. To 
allow OCT to label and visualize specific molecules and cells 
within biological tissues10-12, previous work on OCT contrast 
agents has focused on synthetic particles such as gold 
nanorods13-17. While these materials produce strong NIR 
scattering, these synthetic agents must overcome delivery 
barriers to enter tissues and cells, may accumulate in the body 
after use, and are challenging to couple to intracellular 
processes such as gene expression. If OCT contrast agents 
could instead be made of genetically encodable biomolecules, 
they could serve as biodegradable, cell-produced imaging 
reagents and as reporter genes connected to specific gene 
expression circuits in engineered cells. However, despite 
progress in the development of genetically encoded contrast 
agents for other modalities18, 19, none exists for OCT. 
Here we introduce the first biomolecular, genetically 
encodable OCT contrast agents. They are based on gas 
vesicles (GVs), air-filled protein nanostructures evolved in 
certain photosynthetic microbes as flotation devices to 
maintain optimal access to light and nutrients20, 21. GVs, which 
self-assemble inside the microbes based on a genetic program, 
comprise a hollow gas-filled interior with dimensions on the 
order of 200 nm, enclosed by a 2 nm-thick protein shell that is 
permeable to gas but excludes liquid water. As genetically 
encoded nanostructures, GVs can be expressed 
heterologously22 and have their properties modified through 
genetic engineering23. Recently, the mechanical and magnetic 
properties of GVs were utilized to develop molecular contrast 
agents for ultrasound24 and magnetic resonance imaging25, 26. 
Here we hypothesized that the differential refractive index of 
GVs’ air-filled interior relative to surrounding tissue would 
allow them to serve as genetically encoded reporters for OCT, 
and that their unique material properties would enable 
multiplexed and acoustically erasable molecular imaging. In 
this study, we set out to test these fundamental hypotheses 
through in vitro and in vivo experiments.  
RESULTS  
GVs produce OCT contrast 
The refractive index of air at atmospheric pressure is 1.0, 
which differs substantially from the 1.3–1.4 values of most 
aqueous biological tissues (Fig. 1a). We reasoned that the air 
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contents of GVs would cause these nanostructures to strongly 
scatter incident light, allowing GVs-based contrast agents or 
cells expressing GVs to be visible on OCT images. To test the 
hypothesis, we acquired OCT images of hydrogels containing 
three different GV types derived from Anabaena flos-aquae (Ana 
GVs), Halobacterium salinarum NRC-1 (Halo GVs) and Bacillus 
megaterium (Mega GVs) (Fig. 1b). All three GV types produced 
significant OCT image contrast at nanomolar concentrations 
(Fig. 1c). Halo GVs, which have the largest average volume 
(Fig. 1d and Supplementary Table 1), produced the 
strongest scattering, followed by Ana GVs and Mega GVs, 
with respectively decreasing size (Fig. 1e). However, the 
scattering of each sample did not scale linearly with the total 
amount of gas encapsulated by GV particles (Fig. 1f),  
indicating a dependence on particle size and shape27. These 
results establish the basic ability of GVs to act as contrast 
agents for OCT and indicate that the properties of GVs could 
be tuned to modulate their contrast level. 
 
Acoustic erasure of GV contrast enables background 
subtraction 
The detection of OCT contrast agents within tissues can be 
confounded by endogenous background scattering and 
speckle12. A common solution to mitigate this problem is to 
seek the “brightest” contrast agents that can surpass the 
contrast from a given tissue. However, this puts a stringent 
requirement on the design of contrast agents and often 
demands a relatively high concentration of agents delivered to 
the target tissue. In contrast, GVs have a unique built-in 
mechanism by which they can be distinguished from other 
scatterers. When GVs are subjected to pressure above a 
genetically determined threshold, they become irreversibly 
collapsed, leading to the rapid dissolution of their enclosed 
gas20, leaving behind just their protein shell  (Fig. 1g). The 
required pressure can be delivered remotely and noninvasively 
using a brief pulse from an ultrasound transducer, allowing in 
situ GV collapse25. We therefore hypothesized that ultrasound 
pulses would erase GV-based OCT contrast, allowing it to be 
unambiguously distinguished from background. We tested this 
concept by imaging a hydrogel containing GVs and 
polystyrene nanoparticles as uncollapsible background 
scatterers (Fig. 1h). While it was impossible to identify the GV-
containing region in the initial image, ultrasound treatment 
selectively erased the contrast from GVs, and subtraction of the 
pre- from the post-collapse image resulted in contrast specific 
to the GVs. Together with previous work showing that GV 
 
Fig. 1 | GVs produce OCT contrast that can be erased with ultrasound. a, Schematic drawing of a GV, the gas-filled interior of which 
has a refractive index (red) different from that of the surrounding H2O (blue). b, Representative transmission electron microscopy (TEM) and, c, 
OCT images of GVs from Halobacterium salinarum NRC-1 (Halo), Anabaena flos-aquae (Ana) and Bacillus megaterium (Mega). GVs were embedded in 
a hydrogel phantom for OCT imaging. d, Mean length, width and gas volume (scaled to the areas of the symbols and labeled in attoliter) of Halo, 
Ana and Mega GVs. e, OCT signal intensity (SI) of the concentration series of Halo, Ana and Mega GVs. N = 4 replicates. f, OCT SI normalized 
by the volume of gas contained inside GVs. Error bars represent SEM. g, Representative TEM images of Ana GVs before and after ultrasound 
treatment. h, OCT images of a phantom with regions containing either Ana GVs (OD500, PS = 4) or polystyrene particles (mean diameter = 0.22 
µm, 0.069% w/v, OD500 = 4), before and after the application of ultrasound. Subtracting these two images results in the difference image (colored 
in cyan). Scale bars represent 150 nm (b, g) and 0.5 mm (c, h). The dimensions of GVs in (a) are representative of Ana GVs. 
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collapse does not affect cell viability22, these results suggest that 
acoustic collapse-based background subtraction is a powerful 
approach to enhancing OCT contrast specificity. 
 
Temporal characteristics of OCT images boost the 
detection sensitivity of GVs 
Beyond static images, dynamic OCT provides information on 
the temporal characteristics of a sample. For example, during 
the time elapsed between two consecutive OCT images 
(usually several milliseconds), scatterers may re-orient relative 
to each other within, or move between, coherence volumes10. 
Brownian motion leads to dynamic changes in the speckle 
pattern commonly observed in OCT images of biological 
tissues, and has been used, for example, to measure anisotropic 
scatterer diffusivity28. Hypothesizing that the nanometer size of 
GVs would allow them to undergo significant Brownian 
motion, we wondered whether the temporal characteristics of 
OCT images would enable enhanced detection of GVs or 
contain information about their microscale arrangement in the 
sample. 
To characterize the temporal characteristics of GV-based 
OCT contrast, we recorded a series of OCT images of GVs in 
hydrogel at 100 frames per second (fps) for 2 seconds. In GV 
samples that had an average signal intensity indistinguishable 
from a control polystyrene sample (Fig. 2a), the time trace of 
the signal intensity of individual pixels revealed significantly 
different temporal characteristics (Fig. 2b), which can be 
quantified as the pixel-wise temporal standard deviation (s, 
Fig. 2c). Since the s image provided a much stronger contrast 
than the average intensity (µ) image, we hypothesized that this 
image processing scheme can further boost the sensitivity of 
GV-based OCT contrast. Indeed, even our lowest tested 
concentration of Ana GVs (7.1 pM) showed a clear contrast 
with s processing, which was not seen in a map of µ (Fig. 2d 
 
Fig. 2 | Temporal characteristics of OCT contrast of GVs and GV nanoassembly. a, Representative pixel-wise average signal 
intensity (SI) (µ image) of a series of OCT images collected over 2 seconds at 100 fps of Ana GVs (OD500, PS = 4) and polystyrene particles (mean 
diameter = 0.22 µm, 0.069% w/v). b, Representative time traces of two individual pixels from region containing either GVs or polystyrene 
particles. c, Pixel-wise temporal standard deviation (σ image) of the same samples in (a). d, Representative µ and σ images of a concentration 
series of Ana GVs. e, Diagram of the clustering of surface-biotinylated Ana GVs by streptavidin. f, Representative µ and σ images of clustered 
and unclustered Ana GVs.  g, Mean µ and σ. N = 4 replicates. Error bars represent SEM; scale bars represent 1 mm. 
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and Supplementary Fig. 1). These results establish the 
ability of GV-based contrast agents to be detected with boosted 
sensitivity using dynamic OCT. 
 
Visualizing GV nanoassembly using dynamic OCT 
contrast 
Having established the dynamic contrast behavior of 
independent GVs, we hypothesized that we could toggle their 
spatiotemporal dynamics and OCT contrast via clustering. 
This would enable the engineering of GV-based biosensors 
analogous to particle clustering sensors developed for other 
modalities29-31. We tested this hypothesis using surface-
biotinylated Ana GVs mixed with tetrameric streptavidin as a 
model detectable analyte (Fig. 2e). The addition of 
streptavidin causes the GVs to form clusters of approximately 
2 µm in hydrodynamic radius, ~ 10 times larger than 
individual GVs. Upon clustering, the average OCT image 
intensity had a very minor change, while the temporal s 
decreased dramatically by about an order of magnitude (Fig. 
2, f-g and Supplementary Movie S1). This shows that 
OCT contrast can track not only the concentration, but also 
the microscopic organization of GVs, allowing GVs to act as 
dynamic molecular sensors.  
The decrease in dynamic contrast upon GV clustering is 
the expected result of a reduction in the number and 
movement of independent scatterers.  Within the coherence 
volume, the number of individual GVs is on the order of 104 
to 106 particles, within the optimal range for the phasor-
summed multiple scattering susceptible to particle motion10. 
The clustering of GVs reduces the number of motionally 
independent scatterers to single digits, placing them outside the 
sweet spot for dynamic effects. In addition, clustering decreases 
the freedom of individual GV particles to undergo movements 
such as rotation. Since GVs are anisotropic in shape and may 
scatter light differently depending on their orientation32, 
restricting the reorientation of GVs is also expected to reduce 
the temporal fluctuation of their OCT contrast. 
 
OCT imaging of gene expression 
Having established the OCT contrast of purified GVs, we next 
tested the ability of GVs to act as reporter genes in living cells. 
In particular, OCT has been used to visualize the structure 
bacterial biofilms33, an important class of living materials 
playing key roles in infectious disease, the human microbiome,  
environmental microbiology and synthetic biology34-38. Within 
this context, OCT offers a uniquely suitable combination of 
high spatial resolution, deep penetration and large field of 
view. To test the use of GVs as OCT reporter genes in bacteria, 
we used 3D volumetric OCT to image colonies of bacteria 
cultured on solid agar media. E. coli were engineered to express 
an 11-gene operon, ARG1, comprising a mixture of genes 
from Ana and Mega22. The expression of GVs was controlled 
using a lac operator and the chemical inducer isopropyl ß-D-1-
thiogalactopyranoside (IPTG, Fig. 3a).  
Overnight growth on an agar plate containing IPTG 
allowed the formation of colonies expressing either ARG1 or 
GFP as a negative control for OCT contrast. The growth of 
ARG1 bacteria on a plate without IPTG served as additional, 
uninduced control. The shape of each colony was visible by 3D 
volumetric OCT (Fig. 3b), and GV-expressing colonies could 
clearly be distinguished from controls based on their enhanced 
contrast (Fig. 3c). After the ARG1 colonies were subjected to 
ultrasound pre-treatment to collapse the GVs, their contrast 
became indistinguishable from controls (Fig. 3c). 
Quantification of the OCT image intensity revealed that the 
expression of GVs made bacteria on average 36% brighter 
than controls (Fig. 3d). This indicates that GVs can function 
as OCT reporter genes in living cells. 
 
Fig. 3 | OCT reporter gene enables the imaging of gene expression in bacterial colonies. a, Diagram of the IPTG-inducible 
expression of ARG1 GVs inside E. coli. b, Representative coronal slice (C-scan image) extracted from 3D volumetric OCT image of an E. coli 
colony. c, Representative C-scans of colonies expressing GVs or green fluorescent proteins (GFP), in the presence or absence of the inducer, and 
subjected to ultrasound or left intact. d, Mean average intensity (µ) of E. coli colonies. N = 5 biological replicates. Student’s t-test was performed 
between GVs with and without ultrasound treatment: p < 0.0001, unpaired, d.f. = 15.56. Error bars represent SEM; scale bars represent 1 mm. 
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In vivo visualization of GVs in the retina 
Finally, we tested the ability of GVs to be visualized by OCT 
within the context of living tissue in vivo. In particular, given the 
wide utility of OCT in ophthalmology3, and the need for 
molecular contrast agents to improve the diagnostic 
capabilities of this technique, we assessed whether GVs could 
be imaged in the eye. We injected GVs either intravitreally or 
into the subretinal space of the eye in anesthetized mice, and 
imaged the eye using an FDA-approved spectral domain OCT 
imaging device used in clinical ophthalmology (Fig. 4a).  
GVs provided robust contrast in both the intravitreal (Fig. 
4, b-e) and subretinal (Fig. 4, f-i) space. Furthermore, to 
unambiguously assign the observed contrast to injected GVs 
and test the feasibility of acoustic collapse in vivo, we delivered 
ultrasound pulses using a hand-held clinical transducer directly 
to the mouse eyes. Using the fundus images as a guide, we 
imaged the retina in approximately the same location to see 
the differences in OCT contrast before and after the 
ultrasound treatment, and found that the GV contrast was 
erased completely in both injected locations. These results 
were consistent across animal subjects (Supplementary Fig. 
2, a-b). Likewise, if we injected GVs that were pre-collapsed 
by ultrasound ex vivo, there was no discernable change in OCT 
contrast (Supplementary Fig. 2, c-d). These experiments 
provide a proof of concept for the ability of GVs to serve as 
OCT reporters inside living animals.  
DISCUSSION  
Our results establish GVs as the first biomolecular, genetically 
encodable OCT contrast agents. While this basic capability 
arises from the refractive index difference between GVs’ air 
interior and surrounding water, the contrast abilities of GVs 
are greatly enhanced by the fact that GVs are acoustically 
erasable and that their Brownian motion produces dynamic 
contrast fluctuation. This enables the unambiguous detection 
of GVs among background contrast and allows the 
development of GVs as functional sensors by coupling GV 
clustering to the presence of specific molecules.  
The availability of biomolecular and genetically 
encodable OCT contrast agents may extend the use of OCT 
in new directions. For example, purified GVs have the 
potential to be developed as targeted molecular OCT contrast 
agents. GVs are biodegradable and readily amenable to 
genetic and chemical modification, allowing the addition of 
targeting moieties23. Targeted OCT contrast agents may find 
utility in combination with ophthalmic and intravascular 
OCT39. Furthermore, the genes encoding GVs could be 
incorporated into specific bacterial species, allowing their 
imaging within microbial communities, or the visualization of 
the engineered probiotics being developed as in vivo diagnostic 
and therapeutic agents. By connecting GV expression to 
conditional promoters, OCT contrast could further be used to 
visualize the dynamics of cellular function. Recent work to 
extend GV expression into mammalian cells40 could similarly 
enable the imaging of genetic and cellular therapies, such as 
those in development for inherited retinal degeneration41.  
Building on these results, future studies can be designed to 
address current limitations and establish the wider applicability 
of GVs as genetically encodable OCT contrast agents. First, 
while the detection of GVs on OCT imaging of mouse retina 
demonstrates the feasibility of acoustically erasable OCT 
contrast in vivo, additional work needs to be done to realize the 
full potential of this technology, including the engineering of 
GVs for efficient penetration into tissues such as the retina42, 43 
and an understanding of the biodegradation mechanisms of 
GVs. Secondly, the OCT contrast of GVs could be optimized 
through genetic engineering, since the size, shape and 
mechanical properties of GVs are fully genetically encoded. 
While the size and shape directly influence GVs’ scattering of 
light and Brownian motion, the mechanical properties of GVs 
will determine their acoustic collapse pressure threshold, 
providing a potential avenue towards multiplexed detection. 
Thirdly, the temporal characteristics of GV-derived OCT 
contrast require a more thorough and quantitative 
understanding44, which may be addressed through additional 
simulations and experiments. To this end, existing methods 
optimized to detect dynamic events such as polarization-
sensitive OCT45 and Doppler OCT46, 47 may provide valuable 
information and better sensitivity in detecting GVs. These 
follow-up studies will increase the versatility and practicality of 
using GVs as biomolecular and genetically encodable OCT 
contrast agents, filling an important gap in this photonic 
technology’s unique ability to bridge spatiotemporal resolution 
and depth in biomedical imaging. 
 
Fig. 4 | In vivo imaging of gas vesicles at mouse retina. a, Diagram of the experimental design. Objects are not drawn to scale. 
Representative infrared fundus image (b, d, g, h) and B-scan OCT images (c, e, g, i) of mouse eyes intravitreally (b, c, d, e) or subretinally (f, 
g, h, i) injected with 2 µl of 0.97 nM Ana GVs. Images of the same location of the eyes collected before (b, c, f, g) or after (d, e, h, i) ultrasound 
treatment. The arrows indicate the vitreous or subretinal space, where contrast from gas vesicles was expected. Scale bars represent 0.5 mm.  
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MATERIALS  AND  METHODS  
Preparation, quantification and TEM imaging of GVs 
The protocols to express and purify GVs were described 
previously48. Briefly, among the three genotypes of GVs used 
in this study, Ana GVs and Halo GVs were obtained from their 
native hosts, Anabaena flos-aquae (CCAP strain 1403/13 F) and 
Halobacteria NRC-1 (Carolina Biological Supply), respectively, 
and Mega GVs were obtained by heterologously expressing the 
GV genes from Bacillus megaterium in E. coli. Following the 
harvest and lysis of the cells, GVs were purified through 
multiple rounds of centrifugally assisted floatation. Mega GVs, 
which are natively clustered after purification from bacteria, 
underwent additional steps of unclustering by 6M urea 
treatment, centrifugally assisted floatation and dialysis. The 
concentration of GVs was quantified by the pressure-sensitive 
optical density at 500-nm wavelength (OD500,PS).  OD500,PS was 
then converted to the molar concentration using the relation 
of 114, 47.3 and 2030 pM/OD500,PS for Ana, Halo and Mega 
GVs, respectively (Supplementary Table 1). For TEM 
images, GVs were diluted to OD500, PS ∼ 0.2 and then spotted 
on Formvar/Carbon 200 mesh grids (Ted Pella) that were 
rendered hydrophilic by glow discharging (Emitek K100X). 
After negative staining using 2% uranyl acetate, the samples 
were imaged on a Tecnai T12 LaB6 120 kV TEM.  
 
Clustering of GVs 
Purified Ana GVs were biotinylated using EZ-Link Sulfo-
NHS-LC-biotin (Thermo Fisher Scientific) according to the 
protocol described previously48, and the subsequent clustering 
was adapted from the previous procedure25, 48. Specifically, 
streptavidin (Geno Technology Inc.) was made into a stock 
solution of 5 mg/mL. 1 µL of the stock solution was added into 
every 100 µL of biotinylated Ana GVs at OD500,PS = 16 and 
mixed immediately.  
 
Phantom preparation 
Using a custom-3D-printed caster, a 1% agarose phantom was 
cast in phosphate-buffered saline (PBS) with hemispheric wells 
of diameter ~ 2 mm. Room-temperature PBS containing 
various concentrations of GVs or polystyrene particles (0.069% 
w/v, OD500 = 4, mean diameter = 0.22 µm, Spherotech Inc.) 
were mixed quickly at 1:1 v/v with 2% agarose stock PBS 
solution maintained at 60 °C. 2 µL of the mixture was 
immediately loaded into a well, and the agarose solidified 
within a minute.  Care was taken to avoid bubbles. To prepare 
for OCT imaging, the phantom was submerged in PBS 
solution. 
 
Bacterial colonies and ultrasound treatment 
The plasmid pET28a_T7-ARG1 (Addgene plasmid no. 
106473) was transformed into BL21(A1) one-shot competent 
cells (Thermo Fisher Scientific) for the expression of GVs, and 
GV genes in this plasmid were replaced by the mWasabi gene 
for the expression of GFP. Two-layer LB-Agar plates, each 
with 4 mm in thickness, were made according to a protocol 
adapted from previous literature22. The underlayer contained 
50μg/ml kanamycin, 1.0% L-arabinose, and 0.8 mM IPTG. 
The overlayer contained 50 μg/ml kanamycin and 0.4% 
glucose. The overlayer was poured freshly and allowed to 
equilibrate to room temperature before the transformed cells 
were plated. Plates were then incubated at 30 °C for 24 h. To 
collapse the intracellular GVs in E. coli, ultrasound was applied 
through the bottom of the plates using a Verasonics Vantage 
programmable ultrasound scanning system equipped with the 
L11-4v 128-element linear array transducer using the 
following parameters: transmit frequency 6.25 MHz, transmit 
voltage 25 V, Tx focus = 10 mm and F = 0.1.  
 
OCT imaging and ultrasound treatment of purified 
gas vesicles and bacteria  
The benchtop OCT scanning system used in this study was 
custom-built by OCT Medical Imaging Inc (OCTMI), and 
included a 1320 nm center wavelength 100 kHz swept laser 
(HSL-20-100M, Santec Corporation, Japan), a fiber optic 
interferometer, and a benchtop 2-axis galvo scanner setup. 
The detailed design, components and calculated resolution are 
described (Supplementary Fig. 3). For all the OCT images, 
A-lines were taken at 100 kHz rate with 512 points and an axial 
field of view of 4 ~ 5 mm, and 1000 A-lines were included in 
each B-scan.  For the concentration series of three types of GVs 
(Fig. 1c-f), each B-scan covered an image width of 14.6 mm, 
and in total 800 B-scans were collected while moving the 
imaging plane over a depth of 275 µm and averaged. For 
imaging the temporal characteristics (Fig. 2), the same image 
width was used, and 200 B-scans were collected without 
changing the position of the imaging plane. For bacterial 
colonies (Fig. 3), each B-scan covered an image width of 3.45 
mm, and 1000 B-scans were collected while moving over a 
depth of 3.45 mm, thus allowing a square C-scan for each 
bacterial colony. To collapse GVs in situ (Fig. 1h), the portable 
Lumify Ultrasound System (Philips) was used with the 
following default settings: preset = MSK, depth = 3.5 cm, 
transducer = L12-4, power = 0.0 dB, MI = 1.0. The transducer 
was encapsulated with parafilm, submerged in water, and 
placed close to the sample perpendicular to the direction of 
OCT beams.  
 
Data processing 
The raw OCT interferometric signal generated by the 
balanced detector was first digitized by a 12-bit, 500MS/sec 
waveform digitizer board (ATS9350, Alazar Technologies 
Inc., Canada) into a continuous data stream, which was 
subsequently stored in memory and transferred to the graphics 
processing unit (GPU) for real-time processing and frame-by-
frame display. Each A-scan data array was window filtered, 
dispersion compensated, Fourier transformed, and the 
magnitude of the transformed data was calculated to generate 
depth-resolved OCT intensity data. Due to the exponential 
attenuation of OCT intensity data with respect to depth, 
logarithmic compression, thresholding and scaling were 
applied before the data could be mapped to an 8-bit bitmap 
image file for visualization and storage.  
Fiji was used for subsequent processing and quantification 
of the image intensity49. These bitmap images were first 
converted from logarithmic scale back to linear scale, before 
applying any algorithms such as averaging over multiple 
frames (µ), image subtraction (∆) or calculating standard 
deviation (σ) over a temporal image series. Afterwards, the 
regions of interest (ROIs) were selected, and the value of the 
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average intensity in each ROI was obtained. Such values 
obtained in this linear scale were referred to as SI, µ or σ (Fig. 
1e, 1f, 2b, 2g, 3d). Afterwards, logarithmic compression was 
re-applied before the images were stored and displayed in the 
figures.  
 
In vivo OCT imaging and ultrasound treatment 
All animal experiments were conducted in accordance with the 
Association for Research in Vision and Ophthalmology’s 
statement on the use of animals in ophthalmic research and 
were approved by the University of California San Diego 
Institutional Animal Care and Use Committee. For intravitreal 
and subretinal injections, 4-month-old C57B6/J mice (Jackson 
Laboratories) were anesthetized using a ketamine/xylazine 
cocktail injected intraperitoneally and eyes were locally 
anesthetized using 0.5% proparacaine hydrochloride eyedrop 
(Akorn, Lake Forest, IL). Mice remained anesthetized 
throughout the experiment. GVs were delivered either into the 
vitreous space through intravitreal injection or between the 
retina and retinal pigmented epithelium (RPE) through 
subretinal injection. 2 µl of 0.97 nM intact or collapsed Ana 
GVs in PBS (OD500,PS = 8.5) were injected using 1.5 cm 33-
gauge Hamilton needles (Hamilton Company, Reno, NV). A 
custom contact lens (plano power, black optic zone radius = 
1.70mm, diameter = 3.2mm) (Cantor & Nissel Ltd, Brackley, 
UK) was placed on each mouse eye, and the eyes were dilated 
using 2.5% phenylephrine and 1% tropicamide eye drops 
(Akorn, Lake Forest, IL). OCT images were acquired using 11 
B-scans in a 55 degree x 25 degree pattern (12.6 mm x 5.7 mm) 
by an HRA2/Heidelberg Spectralis (Franklin, MA). To 
collapse GVs inside mouse eyes, Lumify Ultrasound System 
(Philips) and the same parameters were used as described 
above for this device. 
 
Statistical Analysis 
Sample sizes were chosen on the basis of preliminary 
experiments to give sufficient power for the reported statistical 
comparisons. Unless stated otherwise, statistical comparisons 
used two-tailed heteroscedastic t-tests with Welch’s correction.  
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